The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.
What Is The Estimated Market Size Of The Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market In 2026, And How Will Its Value Evolve By 2030?
The market size for glucagon-like peptide (glp)-1 agonists weight loss drugs has seen rapid expansion in recent years. This market is anticipated to expand from $15.5 billion in 2025 to $18.02 billion in 2026, achieving a compound annual growth rate (CAGR) of 16.3%. The historical increase can be ascribed to factors including the rising prevalence of obesity, innovation in diabetes drugs, the burden of lifestyle diseases, the early use of glp-1 for diabetes, and various healthcare awareness campaigns.
The market for glucagon-like peptide (glp)-1 agonists weight loss drugs is poised for significant expansion in the coming years. This market is projected to reach $32.87 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 16.2%. This anticipated growth stems from factors such as the approval of novel GLP-1 drugs, the increasing number of obesity clinics, wider insurance coverage, a greater focus on long-term weight management, and escalating global obesity rates. Prominent trends expected during the forecast period encompass a growing demand for pharmacological weight management solutions, increased utilization of injectable weight loss medications, the broadening adoption of GLP-1 therapies beyond diabetes, the expansion of obesity treatment initiatives, and enhanced patient compliance with long-term therapies.
Access Your Free Sample Report For In-Depth Market Analysis:
What Factors Are Contributing To The Growth Of The Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market?
The growing incidence of obesity is anticipated to stimulate the expansion of the glucagon-like peptide (GLP)-1 agonist weight loss drugs market in the future. Obesity is defined as a health condition marked by an accumulation of excessive body fat, posing health risks. The prevalence of obesity is increasing due to poor dietary choices, including higher consumption of fast food and sugary beverages, which lack adequate nutrition and balance. With the continuous rise in individuals suffering from obesity and associated health issues, there is a greater need for effective therapeutic solutions. This, in turn, is boosting the adoption of glucagon-like peptide (GLP)-1 agonist weight loss drugs, recognized for their efficacy in aiding weight reduction and improving metabolic well-being. For instance, in May 2025, according to the Office for Health Improvement and Disparities, a UK-based government body, from 2023 to 2024, an estimated 64.5% of adults aged 18 and over in England were overweight or living with obesity, up from 64.0% in 2022 to 2023. Consequently, the increasing prevalence of obesity is a key factor driving the growth of the glucagon-like peptide (GLP)-1 agonist weight loss drugs market.
Which Segment Categories Are Included In The Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market Segment Analysis?
The glucagon-like peptide (glp)-1 agonists weight loss drugs market covered in this report is segmented –
1) By Drugs: Semaglutide, Liraglutide, Tirzepatide, Other Drugs
2) By Route of Administration: Parenteral, Oral
3) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Other Pharmacies
Subsegments:
1) By Semaglutide: Ozempic, Wegovy, Rybelsus
2) By Liraglutide: Saxenda, Victoza
3) By Tirzepatide: Mounjaro, Zepbound
4) By Other Drugs: Exenatide, Dulaglutide, Albiglutide, Efpeglenatide
What Trends Are Shaping The Future Of The Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market?
Major companies operating in the glucagon-like peptide (GLP)-1 agonist weight loss drugs market are actively developing advanced obesity treatment solutions designed to boost effectiveness and improve patient outcomes. These obesity treatment solutions refer to therapies that function by mimicking the GLP-1 hormone to help regulate appetite, enhance feelings of fullness, and promote weight loss. Such drugs contribute to managing obesity by improving metabolic function and supporting long-term weight control. For instance, in November 2023, Eli Lilly and Company, a US-based pharmaceutical company, obtained US Food and Drug Administration approval for Zepbound, a medication intended for chronic weight management in adults with obesity or who are overweight with related health conditions such as type 2 diabetes or sleep apnea. The drug functions by activating GIP and GLP-1 hormone receptors to suppress appetite and enhance metabolic function.
Who Are The Active Companies Shaping The Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market?
Major companies operating in the glucagon-like peptide (glp)-1 agonists weight loss drugs market are Novo Nordisk A/S, Eli Lilly and Company, Pfizer Inc., Merck & Co Inc, Boehringer Ingelheim, Hanmi Pharmaceutical, Jiangsu Hengrui Medicine Co Ltd, Zealand Pharma A/S, I-Mab Biopharma Shanghai Co Ltd, Altimmune Inc, BioAge Labs, Innovent Biologics Inc, Viking Therapeutics Inc, Structure Therapeutics Inc, Regor Therapeutics Inc, TheracosBio LLC, Oramed Pharmaceuticals, Amgen Inc, Roche Holding AG, Teva Pharmaceutical Industries Ltd
Get The Full Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market Report:
Where Is The Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market Most Concentrated Geographically?
North America was the largest region in the glucagon-like peptide (GLP) -1 agonists weight loss drugs market in 2025. The regions covered in the glucagon-like peptide (glp)-1 agonists weight loss drugs market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Request A Customized Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market Report For Competitive Insights:
Browse Through More Reports Similar to the Global Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market 2026, By The Business Research Company
Peptide Based Metabolic Disorders Therapeutics Market Report 2026
Glucagon Like Peptide 1 Market Report 2026
https://www.thebusinessresearchcompany.com/report/glucagon-like-peptide-1-global-market-report
Weight Loss Drugs Market Report 2026
https://www.thebusinessresearchcompany.com/report/weight-loss-drugs-global-market-report
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model